In clinical practice, patients with breast cancer exhibiting high Ki‐67 expression typically necessitate conventional chemotherapy, whereas those displaying low Ki‐67 expression may primarily benefit from surgical intervention and endocrine therapy. The gene discussed is MKI67; the disease is breast carcinoma.